Catalyst Wire Dossier Catalyst Wire Dossier

Olvimulogene Nanivacirepvec

olvimulogene nanivacirepvec · Genelux Corporation
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Olvimulogene Nanivacirepvec, covering 2025-09-26 to 2025-09-26. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer [Phase 2]

See pricing